

8 April 2026

Results of Shareholder's General Meeting

Argent BioPharma would like to announce the results from the Company's General Meeting of Shareholders held today, Wednesday, 8 April 2026, in accordance with ASX Listing Rule 3.13.2.

The Company confirms that all motions put to the meeting were voted by poll, with all resolutions carried. Details of the proxy voting and voting outcomes for all motions put to the meeting are set out in the attached.

—Ends—

Authorised for release by the board of directors, for further information please contact:

Argent BioPharma
Roby Zomer
CEO & Managing Director
+61 8 6555 2950
info@argentbiopharma.com

Argent BioPharma
Rowan Harland
Company Secretary
+61 8 6555 2950
info@argentbiopharma.com

Argent BioPharma Ltd. (ASX: RGT) is a clinical-stage biopharmaceutical company developing nano-engineered medicines that restore balance between the nervous and immune systems. Its lead candidates, CannEpi[®] and CimetrA[®], target drug-resistant epilepsy and cytokine-driven inflammatory and autoimmune disorders, respectively. The Company's proprietary delivery platforms are designed to improve penetration across the blood-brain and alveolar-capillary barriers, enabling differentiated efficacy and supporting composition-of-matter protection. With EU-GMP manufacturing, advancing late-stage clinical programs, and a unified Neuro-Immune Modulatory platform, Argent BioPharma is building a high-impact pipeline with a clear focus on urgent unmet needs in CNS and systemic inflammation.

Follow us through our social media channels:

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma

Results of meeting

Listing Rule 3.13.2

Name of entity

Argent Biopharma Limited

ABN/ACN/ARSN/ARBN

116 800 269

Date of meeting

8 April 2026

| Resolutions voted on at the meeting | | | | | If decided by poll/valid | | | | | Proxies received | | | | |
|-------------------------------------|---|--------|---------------|----------|--------------------------|--------|---------|-------|-----------|------------------|---------|-----------|------------|--|
| Resolution | | Result | Voting method | If s250U | For | | Against | | Abstained | For | Against | Abstain | Discretion | |
| No | Short description | | | | Number | % | Number | % | Number | Number | Number | Number | Number | |
| 1 | APPROVAL TO ISSUE SHARES – CANNPAL ACQUISITION | Passed | Poll | N/A | 11,972,963 | 99.66% | 40,602 | 0.34% | 542 | 11,842,541 | 40,602 | 542 | 130,422 | |
| 2 | APPROVAL TO ISSUE SHARES – NEUVIS OPTION | Passed | Poll | N/A | 11,890,673 | 99.05% | 114,026 | 0.95% | 9,208 | 11,769,173 | 114,026 | 9,208 | 121,500 | |
| 3 | APPROVAL TO ISSUE SHARES TO DANIEL ROBINSON | Passed | Poll | N/A | 11,800,525 | 98.51% | 178,439 | 1.49% | 34,943 | 11,678,992 | 178,439 | 34,943 | 121,533 | |
| 4 | APPROVAL TO ISSUE SHARES TO GARY HERMON | Passed | Poll | N/A | 11,800,525 | 98.51% | 178,439 | 1.49% | 34,943 | 11,678,992 | 178,439 | 34,943 | 121,533 | |
| 5 | APPROVAL TO ISSUE SHARES TO ROBY ZOMER | Passed | Poll | N/A | 6,538,180 | 97.78% | 148,464 | 2.22% | 5,327,263 | 6,386,447 | 148,464 | 5,327,263 | 151,733 | |
| 6 | RATIFICATION OF PRIOR ISSUE OF SECURITIES UNDER LISTING RULE 7.1 – GREEN IGUANA PTY LTD | Passed | Poll | N/A | 11,865,857 | 99.06% | 112,611 | 0.94% | 35,439 | 11,744,387 | 112,611 | 35,439 | 121,470 | |
| 7 | APPROVAL TO ISSUE SHARES TO GREEN IGUANA PTY LTD | Passed | Poll | N/A | 11,866,351 | 99.06% | 112,537 | 0.94% | 35,019 | 11,744,810 | 112,537 | 35,019 | 121,541 | |
| 8 | APPROVAL TO ISSUE PERFORMANCE RIGHTS TO ROBY ZOMER | Passed | Poll | N/A | 6,505,756 | 97.29% | 181,523 | 2.71% | 5,326,628 | 6,384,223 | 181,523 | 5,326,628 | 121,533 | |